Display Settings:

Format

Send to:

Choose Destination
We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
    Curr Pharm Des. 2002;8(15):1363-74.

    Indole-3-acetic acids and horseradish peroxidase: a new prodrug/enzyme combination for targeted cancer therapy.

    Source

    Gray Cancer Institute, PO Box 100, Mount Vernon Hospital, Northwood, Middlesex HA6 2JR, UK. wardman@gci.ac.uk

    Abstract

    The radical-cations formed on one-electron oxidation of indole-3-acetic acid (IAA) and its ring-substituted derivatives rapidly fragment, eliminating carbon dioxide from the sidechain and forming a carbon-centred free radical (3-indolylmethyl or skatolyl, or analogues). This radical is reactive towards DNA and possibly other targets in anoxia, but in oxic or hypoxic cells rapidly adds oxygen to form a peroxyl radical. Subsequent products include 3-methylene-2-oxindole or analogues, reactive towards cellular nucleophiles such as thiols and DNA. The one-electron oxidation of indole-3-acetic acids is efficiently achieved by horseradish peroxidase (HRP), not requiring added hydrogen peroxide cofactor. The combination of IAA and HRP is cytotoxic towards mammalian cells, including human tumour cells. Unexpectedly, some halogen-substituted derivatives of IAA are very cytotoxic with HRP even though they are more difficult to oxidize. IAA is tolerated by humans in high doses and HRP is a robust enzyme meeting many of the requirements for targeting to tumours by coupling to antibodies or polymers, or by gene transfection. It is suggested that the indole acetic acids merit further evaluation as potential prodrugs for use in cancer therapy based on targeted delivery of HRP to tumours.

    PMID:
    12052213
    [PubMed - indexed for MEDLINE]

      Supplemental Content

      Icon for Bentham Science Publishers Ltd.

      Save items

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk